Cargando…

PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion

The cation efflux pump Plasmodium falciparum ATPase 4 (PfATP4) maintains Na(+) homeostasis in malaria parasites and has been implicated in the mechanism of action of many structurally diverse antimalarial agents, including >7% of the antimalarial compounds in the Medicines for Malaria Venture’s ‘...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnes, Claudia B. G., Dans, Madeline G., Jonsdottir, Thorey K., Crabb, Brendan S., Gilson, Paul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747762/ https://www.ncbi.nlm.nih.gov/pubmed/36530423 http://dx.doi.org/10.3389/fcimb.2022.1060202

Ejemplares similares

The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites
por: Looker, Oliver, et al.
Publicado: (2022)

Metabolic responses in blood-stage malaria parasites associated with increased and decreased sensitivity to PfATP4 inhibitors
por: Tewari, Shivendra G., et al.
Publicado: (2023)

Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4
por: Ashton, Trent D., et al.
Publicado: (2023)

Novel Antifungal Compounds Discovered in Medicines for Malaria Venture’s Malaria Box
por: Jung, Eric H., et al.
Publicado: (2018)

A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4
por: Gilson, Paul R., et al.
Publicado: (2019)

Na(+) Regulation in the Malaria Parasite Plasmodiumfalciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone Antimalarials
por: Spillman, Natalie J., et al.
Publicado: (2013)

Status of potential PfATP6 molecular markers for artemisinin resistance in Suriname
por: Adhin, Malti R, et al.
Publicado: (2012)

The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs
por: Spillman, Natalie Jane, et al.
Publicado: (2015)

Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach
por: N., Nagasundaram, et al.
Publicado: (2016)

Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites
por: Nugraha, Arifin Budiman, et al.
Publicado: (2019)

Questions over high frequency of mutant PfATP6 haplotypes in traveller isolates
por: Woodrow, Charles J, et al.
Publicado: (2012)

Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
por: Nyagwange, James, et al.
Publicado: (2019)

Malaria Parasite Schizont Egress Antigen-1 Plays an Essential Role in Nuclear Segregation during Schizogony
por: Perrin, Abigail J., et al.
Publicado: (2021)

Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture
por: Tadele, Markos, et al.
Publicado: (2020)

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box
por: Jumani, R. S., et al.
Publicado: (2018)

Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
por: Pasche, Valérian, et al.
Publicado: (2018)

Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box
por: Bhandari, Vasundhra, et al.
Publicado: (2018)

Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18
por: Paiardini, Alessandro, et al.
Publicado: (2015)

In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica
por: Tadele, Markos, et al.
Publicado: (2021)

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
por: Macho, Markéta, et al.
Publicado: (2022)

Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules
por: Subramanian, Gowtham, et al.
Publicado: (2018)

Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections
por: Pillai, Dylan R, et al.
Publicado: (2012)

Impact of maternally derived antibodies to Plasmodium falciparum Schizont Egress Antigen-1 on the endogenous production of anti-PfSEA-1 in offspring
por: Park, Sangshin, et al.
Publicado: (2019)

A G358S mutation in the Plasmodium falciparum Na(+) pump PfATP4 confers clinically-relevant resistance to cipargamin
por: Qiu, Deyun, et al.
Publicado: (2022)

Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture’s Pathogen Box
por: Wall, Gina, et al.
Publicado: (2019)

Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi
por: Almeida-Paes, Rodrigo, et al.
Publicado: (2021)

Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials
por: Flannery, Erika L., et al.
Publicado: (2014)

Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box against Intracellular Leishmania major Amastigotes
por: Khraiwesh, Mozna, et al.
Publicado: (2016)

Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
por: Duffy, Sandra, et al.
Publicado: (2017)

Identification of an Atg8-Atg3 Protein–Protein Interaction Inhibitor from the Medicines for Malaria Venture Malaria Box Active in Blood and Liver Stage Plasmodium falciparum Parasites
por: Hain, Adelaide U.P., et al.
Publicado: (2014)

Erratum for Subramanian et al., “Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules”
por: Subramanian, Gowtham, et al.
Publicado: (2019)

Purified E255L Mutant SERCA1a and Purified PfATP6 Are Sensitive to SERCA-type Inhibitors but Insensitive to Artemisinins
por: Cardi, Delphine, et al.
Publicado: (2010)

Identification of MMV Malaria Box Inhibitors of Perkinsus marinus Using an ATP-Based Bioluminescence Assay
por: Alemán Resto, Yesmalie, et al.
Publicado: (2014)

Compounds from the Medicines for Malaria Venture Box Inhibit In Vitro Growth of Babesia divergens, a Blood-Borne Parasite of Veterinary and Zoonotic Importance
por: Rizk, Mohamed Abdo, et al.
Publicado: (2021)

The Malaria Box: a catalyst for drug discovery
por: Burrows, Jeremy, et al.
Publicado: (2012)

Malaria parasite egress at a glance
por: Tan, Michele S. Y, et al.
Publicado: (2021)

The Knockout for G Protein-Coupled Receptor-Like PfSR25 Increases the Susceptibility of Malaria Parasites to the Antimalarials Lumefantrine and Piperaquine but Not to Medicine for Malaria Venture Compounds
por: Santos, Benedito M., et al.
Publicado: (2021)

In vitro Multistage Malaria Transmission Blocking Activity of Selected Malaria Box Compounds
por: Malebo, Hamisi M, et al.
Publicado: (2020)

Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against Both Trypanosoma cruzi and Trypanosoma brucei
por: Sykes, Melissa L., et al.
Publicado: (2022)

Thinking outside the ‘health’ box: interventions for malaria control
por: Lindsay, Steve
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7fnab0g5d946e4dh7l33gdsbgb